Company news

Dimerix Limited news in 2022

Dimerix Limited's news releases, calls and decks from 2022, newest first.

View company

DMX-200 FSGS Phase 3 Trial Part 1 Recruitment Achieved

December 14, 2022

CLARITY 2.0 COVID-19 Study Outcome

December 12, 2022

Chair address and CEO presentation to AGM

November 28, 2022

Dimerix Receives A$6.0M R&D Tax Incentive Rebate

October 24, 2022

Appendix 4E and 2022 Annual Report

August 28, 2022

CLARITY 2.0 COVID-19 Study Concludes Recruitment

August 17, 2022

New Patent Family Application for DMX-700

August 8, 2022

DMX-700 Study Shows Significant 80% Reduction in Lung Injury

July 3, 2022

REMAP-CAP COVID-19 Study Analysis Update

June 26, 2022

New Clinical Trial for DMX-200 in Diabetic Kidney Disease

June 6, 2022

Phase 3 FSGS Kidney Trial First Patient Recruited

May 30, 2022

Dimerix presentation at Bioshares Biotech Summit

May 11, 2022

FDA IND Approval for Phase 3 Study of DMX-200 in FSGS

May 8, 2022

Dimerix Receives A$3.7M R&D Tax Incentive Rebate

March 28, 2022

DSMB Change to REMAP-CAP COVID-19 Study

February 27, 2022

Half-Year Financial Report & Appendix 4D - 31 December 2021

February 23, 2022

First Regulatory Approval in Europe for DMX-200 FSGS Study

February 1, 2022

Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India

January 10, 2022

Decks in 2022